Structural Insights into Ceftobiprole Inhibition of Pseudomonas aeruginosa Penicillin-Binding Protein 3.

Antimicrobial Agents and Chemotherapy
Vijay KumarFocco van den Akker

Abstract

Ceftobiprole is an advanced-generation broad-spectrum cephalosporin antibiotic with potent and rapid bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, as well as susceptible Gram-negative pathogens, including Pseudomonas sp. pathogens. In the case of Pseudomonas aeruginosa, ceftobiprole acts by inhibiting P. aeruginosa penicillin-binding protein 3 (PBP3). Structural studies were pursued to elucidate the molecular details of this PBP inhibition. The crystal structure of the His-tagged PBP3-ceftobiprole complex revealed a covalent bond between the ligand and the catalytic residue S294. Ceftobiprole binding leads to large active site changes near binding sites for the pyrrolidinone and pyrrolidine rings. The S528 to L536 region adopts a conformation previously not observed in PBP3, including partial unwinding of the α11 helix. These molecular insights can lead to a deeper understanding of β-lactam-PBP interactions that result in major changes in protein structure, as well as suggesting how to fine-tune current inhibitors and to develop novel inhibitors of this PBP.

References

Feb 14, 1971·Journal of Molecular Biology·B Lee, F M Richards
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Paul Emsley, Kevin Cowtan
Dec 8, 2010·Proceedings of the National Academy of Sciences of the United States of America·Seungil HanVeerabahu Shanmugasundaram
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Garib N MurshudovAlexei A Vagin
Jul 21, 2012·The Journal of Biological Chemistry·Andrew L LoveringNatalie C J Strynadka
Aug 16, 2012·Bioorganic & Medicinal Chemistry Letters·Mark J Mitton-FryJennifer A Young
Apr 4, 2014·Journal of Medicinal Chemistry·Jeremy StarrSeungil Han
May 26, 2015·ACS Medicinal Chemistry Letters·Kerry E Murphy-BenenatoShannon X Zhao
Nov 9, 2016·Antimicrobial Agents and Chemotherapy·Wei ChenChristopher Davies
Oct 28, 2018·The Journal of Biological Chemistry·J Andrew N AlexanderNatalie C J Strynadka
Oct 31, 2018·Antimicrobial Agents and Chemotherapy·Michael A PfallerHelio S Sader
Feb 28, 2019·Diagnostic Microbiology and Infectious Disease·Michael A PfallerHelio S Sader

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.